• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Braeburn’s risperidone implant meets primary endpoint in schizophrenia trial

April 27, 2017 By Sarah Faulkner

Braeburn PharmaceuticalsBraeburn Pharmaceuticals said yesterday that a 6-month study of its risperidone implant in patients with schizophrenia or schizoaffective disorder met its primary endpoint.

Risperidone, the most commonly-prescribed therapy for schizophrenia, depends on consistent administration, but patients with schizophrenia sometimes stop taking their medication when their symptoms improve. Long-acting, injectable formulations of risperidone are on the market, but there is no FDA-approved formulation that lasts for 6-months, according to Braeburn.

The trial was designed to compare plasma concentrations of risperidone and its active metabolite between the implant, BB0817, and an oral formulation of the drug. The study enrolled more than 50 patients with schizophrenia who were stable on a daily 4 milligram oral dose of risperidone for at least 8 weeks, Braeburn said. Patients recieved 3 implants just under the skin in their upper arm.

The study met its objectives, demonstrating that plasma concentrations of risperidone and its metabolite were comparable and consistent between the implant and the oral formulation.

“Schizophrenia is a potentially devastating disease, but it can be well-managed through compliance with antipsychotic medication. BB0817 may provide a compelling option to help patients manage schizophrenia, consistent with Braeburn’s commitment to develop long-acting implantable and injectable treatments for stigmatized diseases where adherence is critically important,” president & CEO Behshad Sheldon said in prepared remarks. “This clinical program in schizophrenia represents a strong complement to our initial therapeutic focus in addiction and pain. Looking ahead, we expect results from a Phase III risperidone safety study later this year and are targeting a year-end 2017 filing of a New Drug Application seeking approval for the risperidone implant.”

The Princeton, N.J.-based company also evaluated the safety and efficacy of its implant. Throughout the 6-month trial, 100% of patients remained stable with no clinically significant change in symptoms compared to baseline. Systematic adverse events were similar to those seen with oral risperidone, including akathisia and anxiety.

“Compliance with medication is a very important clinical issue, and without it, serious consequences including relapse and hospitalization are more likely. Preventing non-compliance is an important goal for any successful clinical treatment. The 6-month risperidone implant, if approved, would offer physicians and patients an innovative approach to the treatment of schizophrenia,” principal investigator Dr. Rishi Kakar added. “The implant is administered through a short, in-office procedure, and provides a treatment duration that is more than twice as long as currently-marketed injectables.”

In February, Braeburn pulled its plans for a $150 million initial public offering, citing unstable market conditions.

The company 1st announced plans to go public in late December and in mid-January, Braeburn said it planned to raise $150 million by offering 7,692,308 shares of its common stock at $18.00 to $21.00 apiece.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Braeburn Pharmaceuticals

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS